Contact

Our portfolio

uniQure

Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform. They achieved a landmark approval for their hemophilia B gene therapy, marking a significant advancement in genomic medicine. Building on this success, uniQure is advancing clinical programs for Huntington’s disease and developing a pipeline of preclinical candidates. Orignally spunout as Amsterdam Molecular Therapeutics BV (AMT).

  • Institute: Amsterdam UMC
Industry: Biotechnology, Gene Therapy
  • Founding year: 1998
Visit website

Want to get in contact about uniQure?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

CRCbioscreen
Developing stool-based colorectal cancer screening for early detection.
Haermonics
Preventing post-surgical complications with the PURE pericardial flushing device.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
CRCbioscreen
Developing stool-based colorectal cancer screening for early detection.
Haermonics
Preventing post-surgical complications with the PURE pericardial flushing device.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Explore full AAV portfolio
Contact